Gemfibrozil Tablet
Product Images NDC 71335-1996

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gemfibrozil (NDC 71335-1996). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Additional Adverse Reactions (Additional Adv Drug Reactions)

A data table listing adverse events categorized by likelihood of causal relationship with the drug. It separates adverse events into those with probable causal relationship and those without established causal relationship, covering various body systems such as cardiac, gastrointestinal, central nervous system, eye, genitourinary, musculoskeletal, clinical laboratory, hematopoietic, immunologic, and integumentary.*

FDA Label Image

Adverse Reactions (Adv Reactions)

A table comparing the frequency in percent of various adverse events among subjects receiving Gemfibrozil (N=2046) versus placebo (N=2035). It lists gastrointestinal reactions, acute appendicitis, atrial fibrillation, and other adverse events reported by more than 1% of subjects, with specific percentages shown for each group.*

FDA Label Image

Struct (Structure Gemfibrozil)

Chemical structure of Gemfibrozil showing a benzene ring with two methyl groups and a side chain containing an ether linkage and a carboxylic acid group with additional methyl substitutions.*

FDA Label Image

Table1 (Table 1)

Table presenting reduction in coronary heart disease (CHD) rates by baseline lipid levels over 0 to 5 years from the Helsinki Heart Study. It compares incidence of events per 1000 patients between placebo and gemfibrozil groups across different lipid baseline categories, showing the difference in rates between the groups.*

FDA Label Image

Table2 (Table 2)

A data table titled 'Cardiac Events and All-Cause Mortality (events per 1000 patients) Occurring During the 3.5 Year Open-Label Follow-up to the Helsinki Heart Study' showing cardiac events and all-cause mortality rates among six groups designated by original randomization and drug taken in the follow-up period. The groups are PDrop, PN, PG, GDrop, GN, and GG, with respective patient numbers and event rates listed.*

FDA Label Image

Table3 (Table 3)

A data table titled 'Cardiac Events, Cardiac Deaths, Non-Cardiac Deaths, and All-Cause Mortality in the Helsinki Heart Study, Years 0–8.5,' presenting numbers of cardiac and non-cardiac events and deaths for Gemfibrozil and placebo groups at study start. It includes hazard ratios and confidence intervals comparing Gemfibrozil to placebo, with footnotes explaining analysis methods and definitions.*

FDA Label Image

Label (Lbl713351996)

Label for Gemfibrozil 600 mg oral tablet by Bryant Ranch Prepack. The label compares the product to Lopid 600 mg tablet by Ascent Pharmaceuticals and indicates a quantity of 60 tablets. It includes storage instructions to keep at 20°-25°C and keep out of children's reach. The NDC number 71335-1996-1 and a barcode are present.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.